Efficacy of combination therapy of bortezomib and dexamethasone for seven patients with extramedullary plasmacytoma

被引：0
|
作者：
Kim, Y. S. [1 ]
Kim, E. Y. [1 ]
Park, E. C. [1 ]
机构：
[1] Kosin Univ, Coll Med, Dept Internal Med, Pusan, South Korea
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：164 / 164
页数：1
相关论文
共 50 条
  • [21] Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma.
    Jagannath, S
    Durie, B
    Wolf, J
    Camacho, E
    Irwin, D
    Lutzky, J
    McKinley, M
    Gabayan, E
    Mazumder, A
    Crowley, J
    Vescio, R
    Schenkein, D
    BLOOD, 2005, 106 (11) : 231A - 231A
  • [22] Bortezomib, liposomal doxorubicin and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma
    Falcone, A.
    Sanpaolo, G.
    Bodenizza, C.
    Carella, A. M.
    Dell'Olio, M.
    Mantuano, S.
    Melillo, L.
    Merla, E.
    Scalzulli, F.
    Cascavilla, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 147 - 148
  • [23] Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma
    Moreau, Philippe
    Facon, Thierry
    Touzeau, Cyrille
    Benboubker, Lotfi
    Delain, Martine
    Badamo-Dotzis, Julie
    Phelps, Charles
    Doty, Christopher
    Smit, Hans
    Fourneau, Nele
    Forslund, Ann
    Hellemans, Peter
    Leleu, Xavier
    LEUKEMIA & LYMPHOMA, 2016, 57 (07) : 1546 - 1559
  • [24] Preliminary Results of Bortezomib in Combination with Dexamethasone Followed by Maintenance Therapy
    Aurelio, L.
    De la Rubia, J.
    Vicente, A. I.
    Fernandez, M. J.
    Picon, I.
    Arilla, M. J.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S11 - S11
  • [25] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Shinsuke Iida
    Tatsuo Ichinohe
    Atsushi Shinagawa
    Kenshi Suzuki
    Naoki Takezako
    Masayuki Aoki
    International Journal of Hematology, 2018, 107 : 460 - 467
  • [26] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Ichinohe, Tatsuo
    Shinagawa, Atsushi
    Suzuki, Kenshi
    Takezako, Naoki
    Aoki, Masayuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (04) : 460 - 467
  • [27] Solitary plasmacytoma treated by Lenalidomide-Dexamethasone in combination with radiation therapy
    Fabien, M.
    Schernberg, A.
    Henry, A. Arsene
    Vignon, M.
    Bouscary, D.
    Kirova, Y.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S257 - S258
  • [28] CLINICAL EFFICACY OF VELCADE (BORTEZOMIB) AND DEXAMETHASONE THERAPY IN PATIENTS WITH REFRACTORY OR RELAPSED MULTIPLE MYELOMA
    Ionita, I.
    Cheveresan, M.
    Calamar, D.
    Ionita, C.
    Oros, D.
    Ionita, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 627 - 628
  • [29] Tyrosine Kinase Inhibition in MM? Efficacy of the Combination of Dasatinib/Bortezomib/Dexamethasone
    de Queiroz Crusoe, E.
    Ocio, E. M.
    Maiso, P.
    San-Segundo, L.
    Fernandez, D.
    Garayoa, M.
    Pandiella, A.
    San Miguel, J.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S124 - S124
  • [30] Bortezomib/dexamethasone/selinexorLack of efficacy
    Reactions Weekly, 2024, 1995 (1) : 43 - 43
12345